These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37787790)

  • 1. Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.
    Chao J; Wang S; Wang H; Zhang N; Wang Y; Yang X; Zhu C; Ning C; Zhang X; Xue J; Zhang L; Piao M; Wang M; Yang X; Lu L; Zhao H
    Cancer Immunol Immunother; 2023 Nov; 72(11):3717-3726. PubMed ID: 37787790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study.
    Wang S; Chao J; Wang H; Li S; Wang Y; Zhu C; Zhang N; Piao M; Yang X; Liu K; Xun Z; Sang X; Yang X; Duan W; Zhao H
    Cancer Immunol Immunother; 2024 Oct; 73(12):249. PubMed ID: 39358645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
    Zhu C; Li H; Yang X; Wang S; Wang Y; Zhang N; Wang Y; Xue J; Zhang L; Ning C; Yang X; Xun Z; Chao J; Long J; Sang X; Zhu Z; Zhao H
    Cancer Immunol Immunother; 2023 Sep; 72(9):2949-2960. PubMed ID: 37247023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
    Shi GM; Huang XY; Wu D; Sun HC; Liang F; Ji Y; Chen Y; Yang GH; Lu JC; Meng XL; Wang XY; Sun L; Ge NL; Huang XW; Qiu SJ; Yang XR; Gao Q; He YF; Xu Y; Sun J; Ren ZG; Fan J; Zhou J
    Signal Transduct Target Ther; 2023 Mar; 8(1):106. PubMed ID: 36928584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
    Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
    Front Immunol; 2022; 13():946861. PubMed ID: 35967452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma.
    Huang JX; Liu B; Li Y; Li X; Ding LJ; Wang NY
    Front Oncol; 2023; 13():1204486. PubMed ID: 37664019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative option for advanced unresectable intrahepatic cholangiocarcinoma: a retrospective real-world study.
    Dong Z; Sui C; Lu J; Guo J; Duan K; Wang K; Geng L; Dai B; Yang J
    Front Immunol; 2024; 15():1463574. PubMed ID: 39290704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy.
    Deng M; Li S; Wang Q; Zhao R; Zou J; Lin W; Mei J; Wei W; Guo R
    Ann Med; 2022 Dec; 54(1):803-811. PubMed ID: 35272564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma.
    Lin YS; Li S; Yang X; Guo RP; Huang YH; Bai KH; Weng J; Yun JP
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):309. PubMed ID: 38890157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world outcomes of chemotherapy plus immune checkpoint inhibitors versus chemotherapy alone in advanced, unresectable, and recurrent intrahepatic cholangiocarcinoma.
    Madzikatire TB; Heng S; Gu H; Shan Y; Lin E; Banda J; Debora A; Madziva BA; Bowa MJ; Mudhuri MG; Bwalya C
    Front Immunol; 2024; 15():1390887. PubMed ID: 38846939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study.
    Ning Z; Xie L; Yan X; Hua Y; Shi W; Lin J; Xu L; Meng Z
    Br J Radiol; 2023 Oct; 96(1150):20230079. PubMed ID: 37660471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma.
    Huang Y; Du Z; Kan A; He M; Li H; Lai Z; Wen D; Huang L; Li Q; Xu L; Shi M
    Front Immunol; 2024; 15():1260191. PubMed ID: 38384459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
    Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
    Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma.
    Lin Z; Zou X; Hu X; Huang D; Chen Y; Lin J; Li X; Zhang J
    Sci Rep; 2024 Oct; 14(1):23961. PubMed ID: 39397104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.
    Zhu C; Xue J; Wang Y; Wang S; Zhang N; Wang Y; Zhang L; Yang X; Long J; Yang X; Sang X; Zhao H
    Front Immunol; 2023; 14():1109292. PubMed ID: 36742297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.
    Wang Y; Yang X; Wang Y; Xue J; Zhang N; Yang X; Cong N; Zhang J; Zhu C; Zhang L; Hou X; Zhao H
    Cancer Immunol Immunother; 2023 Jul; 72(7):2197-2204. PubMed ID: 36856834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 20. Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.
    Kim H; Kim J; Byeon S; Jang KT; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
    Oncology; 2021; 99(6):365-372. PubMed ID: 33730723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.